Isotechnika Pharma (AUPH) Rating Increased to Hold at BidaskClub

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Other equities analysts also recently issued reports about the stock. Seaport Global Securities reiterated a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a report on Friday, March 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price objective on shares of Isotechnika Pharma in a report on Thursday, May 10th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Isotechnika Pharma in a research note on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, April 5th. Finally, ValuEngine upgraded shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $10.92.

Isotechnika Pharma opened at $6.11 on Wednesday, MarketBeat Ratings reports. Isotechnika Pharma has a one year low of $6.28 and a one year high of $6.64.

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). Isotechnika Pharma had a negative net margin of 8,193.08% and a negative return on equity of 20.67%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. analysts forecast that Isotechnika Pharma will post -0.7 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank acquired a new position in shares of Isotechnika Pharma in the fourth quarter valued at about $421,000. Goldman Sachs Group Inc. grew its stake in shares of Isotechnika Pharma by 36.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after acquiring an additional 319,639 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Isotechnika Pharma by 33.2% in the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after acquiring an additional 414,400 shares in the last quarter. Spark Investment Management LLC acquired a new position in shares of Isotechnika Pharma in the fourth quarter valued at about $153,000. Finally, Hudson Bay Capital Management LP grew its stake in shares of Isotechnika Pharma by 20.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $2,039,000 after acquiring an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 28.58% of the company’s stock.

About Isotechnika Pharma

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.

Analyst Recommendations for Isotechnika Pharma (NASDAQ:AUPH)

Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit